Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Gisslinger

Showing results (91-100 of 95) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 95 results.
Leukemia|May 4, 2017
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependenceA Tefferi, H K Al-Ali, G Barosi, et al.
Leukemia|July 27, 2017
Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational statusB Kubesova, S Pavlova, J Malcikova, et al.
Blood Cancer Journal|March 9, 2013
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH SymposiumA Tefferi, O Abdel-Wahab, F Cervantes, et al.
Leukemia|June 7, 2013
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international studyA Tefferi, E Rumi, G Finazzi, et al.
Leukemia|August 26, 2014
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)G Barosi, A Tefferi, C Besses, et al.
Pageof 10

Showing results (91-100 of 95) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 95 results.
Leukemia|May 4, 2017
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependenceA Tefferi, H K Al-Ali, G Barosi, et al.
Leukemia|July 27, 2017
Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational statusB Kubesova, S Pavlova, J Malcikova, et al.
Blood Cancer Journal|March 9, 2013
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH SymposiumA Tefferi, O Abdel-Wahab, F Cervantes, et al.
Leukemia|June 7, 2013
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international studyA Tefferi, E Rumi, G Finazzi, et al.
Leukemia|August 26, 2014
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)G Barosi, A Tefferi, C Besses, et al.
Pageof 10